Observational studyClinical endocrinology2016
TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Observational study in Clinical endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Computational and mathematical methods in medicine · 2022Pooled it
- Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Endocrine · 2020Pooled it
- The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.Medicine · 2018Pooled it
- Value of TERT promoter mutations for early outcomes in papillary thyroid cancer.Endocrine-related cancer · 2026Article
- Interplay of BRAF and TERT promoter mutations and Ki67 proliferation index in papillary thyroid carcinoma in Central Asians.BMC endocrine disorders · 2026Article
- Detection of TERT Promoter Mutations in Papillary Thyroid Carcinoma Using Droplet Digital PCR and Their Association with Aggressive Tumor Features.International journal of molecular sciences · 2026Article
- Integrating TERT promoter mutations into risk stratification of papillary thyroid cancer.Endocrine connections · 2026Article
- Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.The Lancet. Oncology · 2025Article
- AURKB and PI3K/AKT/mTOR pathways converge to regulateiScience · 2025Article
- Regulatory SNP of TERT promoter accompanied by C228T andOncology letters · 2025Article
- Prediction of BRAF and TERT status in PTCs by machine learning-based ultrasound radiomics methods: A multicenter study.Journal of clinical & translational endocrinology · 2025Article
- Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.Frontiers in immunology · 2025Review
- Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.Clinical and experimental medicine · 2024Article
- Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.Endocrine · 2024Article
- The prognostic power of gene mutations in thyroid cancer.Endocrine connections · 2024Review
- Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years.Frontiers in endocrinology · 2024Article
- Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.Molecular cancer research : MCR · 2023Article
- Mechanistic Insights of Thyroid Cancer Progression.Endocrinology · 2023Review
- InTERTwined: howCurrent opinion in endocrine and metabolic research · 2023Article
- Telomerase reactivation induces progression of mouse BrafbioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextTERT promoter mutations have been associated with adverse prognosis in papillary thyroid carcinomas (PTCs).
objectiveWe investigated the association between TERT promoter mutations and survival from PTC.
designRetrospective observational cohort study. PATIENTS: Eighty consecutive patients with PTC who underwent surgery between 1990 and 2003. MEASUREMENTS: TERT promoter was genotyped in DNA from 80 archival PTCs by Sanger sequencing. Median follow-up was 106 months (range 1-270). Outcomes analysis was stratified according to disease and overall survival status. For each parameter, relative risk (RR) adjusted for age at first surgery and gender was estimated. Both univariate and multivariate analyses were performed using logistic regression, Kaplan-Meier survival analysis and Cox regression models.
resultsPTCs from 11 patients (14%) contained either C228T or C250T TERT promoter mutation. TERT mutations were significantly associated with adverse prognostic features such as older age (P = 0·002), male gender (P = 0·01) and Stage IV disease (P = 0·03). Four patients died from PTC during follow-up: 3 patients with TERT mutations (27%) and one without (1·5%). Disease-related mortality rate with or without TERT mutations was 33·7 vs 1·6 per 1000 patient-years respectively, that is 10 (95% CI = 1·0-104·1, P = 0·05) fold higher, after adjustment for age at first surgery and gender. The combination of TERT promoter mutation and BRAF(V) (600E) significantly increased disease-related death risk (P = 0·002). TERT mutations increased expression of a reporter gene in thyroid cells containing BRAF(V) (600E) .
conclusionsTERT promoter mutations are a major indicator of death due to PTCs. Conversely, absence of TERT mutations portends better survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.